FDA Clears Freenome's SimpleScreen CRC Blood Test, Triggering $100M Abbott Milestone
Summary
Freenome's SimpleScreen CRC blood test for colorectal cancer screening won FDA approval, unlocking a $100 million milestone payment from partner Abbott and a U.S. commercial launch this fall.
Key Events · Product Development and Regulatory · PCSC
-
FDA Approval of SimpleScreen CRC
Marking the company's first commercial product, the FDA approved Freenome's blood-based colorectal cancer screening test for adults 45 and older at average risk.
-
$100M Milestone Payment from Abbott
Under the August 2025 commercial agreement, FDA approval triggers a $100 million payment from Abbott, providing significant non-dilutive capital.
-
Abbott to Commercialize in U.S.
Leveraging its Cologuard infrastructure and Nexus platform, Abbott will exclusively launch SimpleScreen CRC in the U.S. this fall to drive adoption.
-
Strong Clinical Validation Data
In the 48,000-patient PREEMPT CRC study, the test demonstrated 81.1% sensitivity for colorectal cancer and 90.4% specificity for advanced neoplasia.
Analysis · PCSC · Industrial Applications And Services
A transformative moment for the recently merged company: Freenome's first commercial product, SimpleScreen CRC, has secured FDA approval. The green light unlocks a $100 million milestone payment from Abbott, delivering critical non-dilutive capital. Abbott will handle exclusive U.S. commercialization, tapping its established Cologuard infrastructure. With Medicare coverage secured and inclusion in American Cancer Society guidelines expected, the test targets a vast unmet need among 60 million unscreened Americans. The approval de-risks Freenome's platform, validates its multiomics approach, and paves the way for pipeline expansion.
At the time of this filing, PCSC was trading at $12.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $123.2M. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.